Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics, Inc. ( MYGN ) Q2 2026 Earnings Call July 30, 2026 4:30 PM EDT Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Brian Donnelly - Chief Commercial Officer Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Kyle Boucher - TD Cowen, Research Division Skye Gilbert - Piper Sandler & Co., Research Division Presentation Operator Good day, and thank you for standing by. Welcome to Myriad Genetics' Second Quarter 2026 Financial Earnings Conference Call. Operator Instructions Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today, Matt Scalo. Please go ahead. Matthew Scalo Senior Vice President of Investor Relations Good afternoon, and welcome to Myriad Genetics' Second Quarter 2026 Earnings Call. During the call, we will review financial results we released today, and afterwards, we will host a Q&A session. Our earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations. On the call with me today are Sam Raha, our President and Chief Executive Officer; Ben Wheeler, our Chief Financial Officer; and Brian Donnelly, our Chief Commercial Officer. Also joining for Q&A will be Mark Verratti, our Chief Operating Officer. This call can be heard live via webcast at investor.myriad.com, and a recording will be archived in the investor section of our website along with this slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management's current expectations. The actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer